Miles D. Thompson

Dr. Miles D. Thompson

Department of Pediatrics, University of California, San Diego 92093, CA, USA
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PKPeter M Krawitz
Peter M Krawitz
MSMichal R Schweiger
Michal R Schweiger
CRChristian Rödelsperger
Christian Rödelsperger
CMCarlo Marcelis
Carlo Marcelis
UKUwe Kölsch
Uwe Kölsch
PRPeter N. Robinson
Peter N. Robinson
Hyperphosphatasia mental retardation (HPMR) syndrome is an autosomal recessive form of mental retardation with distinct facial features and elevated serum alkaline phosphatase. We performed whole-exome sequencing in three siblings of a nonconsanguineous union with HPMR and performed computational inference of regions identical by descent in all siblings to establish PIGV, encoding a member of the GPI-anchor biosynthesis pathway, as the gene mutated in HPMR. We identified homozygous or compound heterozygous mutations in PIGV in three additional families.

1 May 2007 in Epidemiology
Verified
Journal Article
Closed access
JRJoel G. Ray
Joel G. Ray
PWPhilip R. Wyatt
Philip R. Wyatt
Miles D. ThompsonMiles D. Thompson
Miles D. Thompson
MVMarian J. Vermeulen
Marian J. Vermeulen
CMChris Meier
Chris Meier
DCDavid E. C. Cole
David E. C. Cole
Low maternal vitamin B12 status may be a risk factor for neural tube defects (NTDs). Prior studies used relatively insensitive measures of B12, did not adjust for folate levels, and were conducted in countries without folic acid food fortification. In Canada, flour has been fortified with folic acid since mid-1997. We completed a population-based case–control study in Ontario. We measured serum holotranscobalamin (holoTC), a sensitive indicator of B12 status, at 15 to 20 weeks’ gestation. There were 89 women with an NTD and 422 unaffected pregnant controls. A low serum holoTC was defined as less than 55.3 pmol/L, the bottom quartile value in the controls. The geometric mean serum holoTC levels were 67.8 pmol/L in cases and 81.2 pmol/L in controls. There was a trend of increasing risk with lower levels of holoTC, reaching an adjusted odds ratio of 2.9 (95% confidence interval = 1.2–6.9) when comparing the lowest versus highest quartile. There was almost a tripling in the risk for NTD in the presence of low maternal B12 status, measured by holoTC. The benefits of adding synthetic B12 to current recommendations for periconceptional folic acid tablet supplements or folic-acid-fortified foods need to be considered. It remains to be determined what fraction of NTD cases in a universally folate-fortified environment might be prevented by higher periconceptional intake of B12.

7 August 2006 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
VCValérie Capra
Valérie Capra
Miles D. ThompsonMiles D. Thompson
Miles D. Thompson
ASAngelo Sala
Angelo Sala
DCDavid E. Cole
David E. Cole
GFGiancarlo Folco
Giancarlo Folco
GRGianenrico Rovati
Gianenrico Rovati

1 July 2012 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PKPeter M. Krawitz
Peter M. Krawitz
YMYoshiko Murakami
Yoshiko Murakami
JHJochen Hecht
Jochen Hecht
UKUlrike Krüger
Ulrike Krüger
SHSusan E. Holder
Susan E. Holder
DHDenise Horn
Denise Horn

1 May 2000 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
DVD J Vandenbergh
D J Vandenbergh
Miles D. ThompsonMiles D. Thompson
Miles D. Thompson
ECE H Cook
E H Cook
EBE Bendahhou
E Bendahhou
TNT Nguyen
T Nguyen
GUG R Uhl
G R Uhl

1 January 2005 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
Miles D. ThompsonMiles D. Thompson
Miles D. Thompson
WBW. McIntyre Burnham
W. McIntyre Burnham
DCDavid E. C. Cole
David E. C. Cole
Genetic variation in G-protein coupled receptors (GPCRs) is associated with a wide spectrum of disease phenotypes and predispositions that are of special significance because they are the targets of therapeutic agents. Each variant provides an opportunity to understand receptor function that complements a plethora of available in vitro data elucidating the pharmacology of the GPCRs. For example, discrete portions of the proximal tail of the dopamine D1 receptor have been discovered, in vitro, that may be involved in desensitization, recycling and trafficking. Similar in vitro strategies have been used to elucidate naturally occurring GPCR mutations. Inactive, over-active or constitutively active receptors have been identified by changes in ligand binding, G-protein coupling, receptor desensitization and receptor recycling. Selected examples reviewed include those disorders resulting from mutations in rhodopsin, thyrotropin, luteinizing hormone, vasopressin and angiotensin receptors. By comparison, the recurrent pharmacogenetic variants are more likely to result in an altered predisposition to complex disease in the population. These common variants may affect receptor sequence without intrinsic phenotype change or spontaneous induction of disease and yet result in significant alteration in drug efficacy. These pharmacogenetic phenomena will be reviewed with respect to a limited sampling of GPCR systems including the orexin/hypocretin system, the β2 adrenergic receptors the cysteinyl leukotriene receptors and the calcium-sensing receptor. These developments will be discussed with respect to strategies for drug discovery that take into account the potential for the development of drugs targeted at mutated and wild-type proteins.